John Potthoff Net Worth

The estimated Net Worth of John Gary Potthoff is at least $69.4 mil dollars as of 24 June 2021. John Potthoff owns over 16,314 units of Chembio Diagnostics stock worth over $24,880 and over the last 6 years he sold CEMI stock worth over $0. In addition, he makes $44,500 as Independent Director at Chembio Diagnostics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Potthoff CEMI stock SEC Form 4 insiders trading

John has made over 3 trades of the Chembio Diagnostics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,314 units of CEMI stock worth $7,504 on 24 June 2021.

The largest trade he's ever made was buying 20,000 units of Chembio Diagnostics stock on 14 November 2018 worth over $116,200. On average, John trades about 7,719 units every 159 days since 2018. As of 24 June 2021 he still owns at least 54,086 units of Chembio Diagnostics stock.

You can see the complete history of John Potthoff stock trades at the bottom of the page.

John Potthoff biography

Dr. John Gary Potthoff Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Dr. Potthoff has 25 years of experience in the clinical research services industry, with deep ties to diagnostics and pharmaceutical companies. He is currently the CEO of Elligo Health Research, a clinical research company aimed at being the preeminent provider of clinical research infrastructure services and technologies. Prior to Elligo, Dr. Potthoff was the CEO of Theorem Clinical Research, where he led the company through a period of significant growth and its acquisition by Chiltern International. Previously, Dr. Potthoff was the CEO and founder of Tanistry, Inc., a contract research organization focused on the central nervous system.

What is the salary of John Potthoff?

As the Independent Director of Chembio Diagnostics, the total compensation of John Potthoff at Chembio Diagnostics is $44,500. There are 5 executives at Chembio Diagnostics getting paid more, with Javan Esfandiari having the highest compensation of $557,521.

What's John Potthoff's mailing address?

John's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.

Insiders trading at Chembio Diagnostics

Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert, eRichard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.

What does Chembio Diagnostics do?

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Complete history of John Potthoff stock trades at Chembio Diagnostics

Chembio Diagnostics executives and stock owners

Chembio Diagnostics executives and other stock owners filed with the SEC include:

• Javan Esfandiari,
  Exec. VP and Chief Science & Technology Officer
• Richard L. Eberly,
  Pres, CEO & Director
• Javan Esfandiari,
  Executive Vice President, Chief Scientific And Technology Officer
• Neil Goldman,
  Chief Financial Officer, Executive Vice President
• Katherine Davis,
  Independent Director
• John Potthoff,
  Independent Director
• Gail Page,
  Executive Chairman of the Board
• Mary Polan,
  Independent Director
• Lynn Lewis,
  Investor Relations Contact Officer
• Chuck Caso,
  Vice President of Sales and Marketing for North America
• Richard Eberly,
  President, Chief Executive Officer, Director
• Stella Rivera,
  VP of HR
• Atif Rizvi,
  VP of Fin.
• Dr. Konstantin Lyashchenko,
  Research Director of Chembio Diagnostic Systems Inc
• Charles Caso,
  VP of Sales & Marketing
• Paul J. Angelico,
  VP of Global Operations
• Peter Kissinger,
  Director
• Richard J Larkin,
  Chief Financial Officer
• Barbara A De Buono,
  Director
• John J Iii Sperzel,
  CEO
• Robert L Aromando,
  Sr VP, Commercial Operations
• Alan Carus,
  Director
• Lawrence A. Siebert,
  President
• Leslie Teso Lichtman,
  
• Norman H Pessin Brian L. Pe...,
  
• Gary Meller,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer
• David Gyorke,
  See Remarks
• Robert Passas,
  See Remarks
• Avi Pelossof,
  Vice President
• Gerald A Eppner,
  Director
• James D Merselis,
  Director
• Capital Master Llc Crestvie...,
  
• David Acheson,
  
• Credit Advisors, Llcpercept...,
  
• David William Bespalko,
  
• Lawrence J. Steenvoorden,
  See remarks
• Charles Caso,
  See Remarks
• Paul Angelico,
  See remarks